Philip Bonomi to Megestrol Acetate
This is a "connection" page, showing publications Philip Bonomi has written about Megestrol Acetate.
Connection Strength
0.081
-
Quantitative estrogen and progesterone receptor levels related to progression-free interval in advanced breast cancer patients treated with megestrol acetate or tamoxifen. Semin Oncol. 1988 Apr; 15(2 Suppl 1):26-33.
Score: 0.020
-
Megestrol acetate used as primary hormonal therapy in stage D prostatic cancer. Semin Oncol. 1985 Mar; 12(1 Suppl 1):36-9.
Score: 0.017
-
Primary hormonal therapy of advanced breast cancer with megestrol acetate: predictive value of estrogen receptor and progesterone receptor levels. Semin Oncol. 1985 Mar; 12(1 Suppl 1):48-54.
Score: 0.017
-
Megestrol acetate as primary hormonal therapy for advanced breast cancer. Semin Oncol. 1988 Apr; 15(2 Suppl 1):34-7.
Score: 0.005
-
Sequential hormone therapy for advanced breast cancer. Semin Oncol. 1988 Apr; 15(2 Suppl 1):38-43.
Score: 0.005
-
Megestrol acetate v tamoxifen in advanced breast cancer: correlation of hormone receptors and response. Semin Oncol. 1986 Dec; 13(4 Suppl 4):9-14.
Score: 0.005
-
Megestrol acetate: first-line therapy for advanced breast cancer. Semin Oncol. 1986 Dec; 13(4 Suppl 4):15-9.
Score: 0.005
-
Metastatic breast cancer: preliminary results with oral hormonal therapy. Semin Oncol. 1985 Dec; 12(4 Suppl 6):61-4.
Score: 0.004
-
Progesterone receptor level as a predictor of response to megestrol acetate in advanced breast cancer: a retrospective study. Cancer Treat Rep. 1983 Jul-Aug; 67(7-8):717-20.
Score: 0.004